zachthewf
Joined 15 years ago
Joined 15 years ago
- How have things looked since passage? Has there been a lot of interest from companies and patients or is demand the bottleneck? Not that many people in Montana...
- What sort of new business models does this open up? e.g. Roivant for abandoned phase 1 assets?
- Does this lower the barrier for treating new indications, e.g. age related conditions like sarcopenia?
- Any particular rules on telehealth?
Long but totally heartbreaking.
BTW: when you say you manufacture the drugs, I assume that means you're buying from an API supplier, but do you actually mean you're synthesizing it yourself?
You can also do this if you're not shutting down, but it's probably not worth it.
I'm not open-minded to arguments about utility, given that I personally witnessed LLMs evolve from interesting but useless toys to insanely helpful tools I use every day.
currently @ boltz bio, former yc founder
zachocean.com